Innovative polatuzumab vedotin plus R-CHP therapy reshapes treatment of older adult patients with diffuse large B-cell lymphoma.

The following is a summary of “Identification of molecular clusters and a risk prognosis model for diffuse large B-cell ...

The real-world safety profile of tisagenlecleucel appears to be more favourable than that reported in the JULIET study, which led to its FDA approval.

The patient was diagnosed with nongerminal-center B cell diffuse large B-cell lymphoma (DLBCL) 1 year after being diagnosed with primary biliary cholangitis (PBC).

Experts discuss the 5-year efficacy and safety outcomes of polatuzumab in diffuse large B-cell lymphoma (DLBCL), highlighting ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

Experts discuss polatuzumab’s effectiveness across germinal center B-cell (GCB) and activated B-cell (ABC) diffuse large ...

Mark Hoppus, the co-founder, lead vocalist, and bassist of the rock band Blink-182, recently opened up about his struggles ...

Bravo star Brittany Cartwright revealed that her and Jax Taylor’s 3-year-old son, Cruz, was diagnosed with autism after ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

clonoSEQ testing for patients with MCL is currently available for clinical use as a laboratory-developed test performed at Adaptive's CLIA-certified lab in Seattle. clonoSEQ testing in MCL has also ...